Former Assistant District Attorney Indicted on Bribery, Money[...]
Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Notification Letter and Reply Form to Non registered Shareholders[...]
05/09/2022 | Press release | Distributed by Public on 05/08/2022 17:39
Please select the service you want to use:
Smartlinks | Sumitomo Dainippon Pharma Co. Ltd. | News | Health | Finance | Security Markets | Security Markets | Company News | Public Companies | Pharmaceutical Companies | Börse Frankfurt | Börse Berlin | Börse Düsseldorf | Börse München | Börse Stuttgart | OTC Markets | Tokyo Stock Exchange (TSE) | Chi-X Japan | SBI Japannext
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact